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& Abstract
Background: Sickle cell disease (SCD) is a worldwide distrib-
uted hereditary red cell disorder. The principal clinical
manifestations of SCD are the chronic hemolytic anemia
and the acute vaso-occlusive crisis (VOCs), which are mainly
characterized by ischemic/reperfusion tissue injury. Pain is the
main symptom of VOCs, and its management is still a
challenge for hematologists, requiring a multidisciplinary
approach.
Methods: We carried out a crossover study on adult SCD
patients, who received two different types of multimodal
analgesia during two separate severe VOCs with time interval
between VOCs of at least 6 months. The first VOC episode
was treated with ketorolac (0.86 mg/kg/day) and tramadol
(7.2 mg/kg/day) (TK treatment). In the second VOC episode,
fentanyl buccal tablet (FBT; 100 lg) was introduced in a
single dose after three hours from the beginning of TK
analgesia (TKF treatment). We focused on the first 24 hours
of acute pain management. The primary efficacy measure
was the time-weighted-sum of pain intensity differences
(SPID24). The secondary efficacy measures included the pain
intensity difference (PID), the total pain relief (TOTPAR), and
the time-wighted sum of anxiety (SAID24).
Results: SPID24 was significantly higher in TKF than in TK
treatment. All the secondary measures were significantly
ameliorated in TKF compared to TK treatment, withoutmajor
opioid side effects. Patients satisfaction was higher with TKF
treatment than with TK one.
Conclusions: We propose that VOCs might require break-
through pain drug strategy as vaso-occlusive phenomena
and enhanced vasoconstriction promoting acute ischemic
pain component exacerbate the continuous pain of VOCs.
FBT might be a powerful and feasible tool in early
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management of acute pain during VOCs in emergency
departments. &
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INTRODUCTION
Sickle cell disease (SCD) is a worldwide distributed
hereditary red cell disorder characterized by the synthe-
sis of pathological hemoglobin S (HbS).1, 2 The principal
clinical manifestations of SCD are chronic hemolytic
anemia and acute vaso-occlusive crisis (VOCs), which
are related to ischemic/reperfusion tissue injury.1, 3, 4
SCD patients are the major users of emergency depart-
ments (EDs) compared to subjects with other severe
hemoglobinopathies due to VOCs.5 Pain is the main
symptom of VOCs, and its management is still a
challenge for hematologists, requiring a multidisciplin-
ary approach.6 Although protocols for control of acute
pain in SCD have been developed in the last decade,6–10
SCD patients still feel undertreated.11 Different mech-
anisms are involved in pain generation during VOCs: (i)
the ischemic/reperfusion injury and activation of inflam-
matory response; (ii) the local release of sensitizing
mediators, contributing to local vasodilation and
edema; (iii) the neuropathic component sustained by
an aberrant stimulation of central and peripheral ner-
vous system.6 Pain treatment with either nonsteroidal
anti-inflammatory drugs (NSAID), such as ketopro-
fen,12 or morphine13, 14 is partially successful in man-
agement of VOCs, suggesting that the biocomplexity of
pain origin in SCD requires a multitarget pharmacolog-
ical approach. Recently, we reported that multimodal
analgesia with ketorolac, a NSAID, and tramadol, an
atypical opioid, is effective in management of acute pain
during severe VOCs.15 Multimodal analgesia is largely
used in pain control related to major surgery or to
chronic pain and is based on the co-administration of
drugs with different pharmacological mechanisms, con-
trolling pain of multiple origins.16, 17 In SCD, early
studies on pain management during VOCs have shown
that fast-acting opioids such as fentanyl might be an
interesting therapeutic tool when associated to major
opioids.18–20 However, its route of administration has
largely limited fentanyl introduction in routine proto-
cols for acute pain control in SCD. The recent develop-
ment of rapid-onset fentanyl formulations that use less
invasive delivery such as oral mucosa has allowed the
introduction of fentanyl for management of acute pain
of cancer and noncancer origin.10, 21–23 Among the
rapid-onset fentanyl formulations, FBT seems to be a
feasible tool as breakthrough pain (BTP) drug in
treatment of acute pain in ED.18, 22
METHODS
Study Design
This is a crossover clinical study on a group of adult
patients with SCD referred to the Department of
Medicine, University of Verona, Italy, between January
2010 and July 2013. The study was carried out
according to the guidelines of the local ethical commit-
tee. Each patient was informed on the ongoing study,
and written informed consent was obtained. Data were
anonymously collected. The study involved SCD
patients aged 18–45 years with severe painful VOCs,
defined as bone pain (ie, extremities, hips, or back) or
abdominal pain, for which no other clinical explanation
was identified, with a visual analogue scale pain level
(VAS) of 7 or more. Each hospitalization was defined as
an episode of VOC.15 Patients were not considered if
they had a history of opioid consumption during the
2 weeks before the VOC. Other exclusion criteria were
contraindication to opioids administration (such as a
history of opioids misuse and abuse), altered conscious
state, pregnancy or lactating, hepatic and/or renal
failure, gastritis or peptic ulcer, allergies, or other
contraindications to any ingredient in the study drugs.
The presence of cardiopulmonary disease, medical, or
psychiatric disease that, in the opinion of the investiga-
tors, might compromise the collection of the study data
were also exclusion criteria.
Study Procedures
At the admission to our Department, two physicians
independently evaluated the SCD patients and attrib-
uted a clinical level of pain severity and pain localiza-
tion. When the VAS pain score was 7 or more, the VOC
event was defined as severe pain VOC episode.15, 24 We
carried out a power analysis for this study, and we
identified a number of 19 to demonstrate with a 0.8
power and a level of significance of 0.05 a reduction in
VAS of at least 1.3 when FBT is added to standard
treatment on control of acute pain in SCD. This
prediction is in agreement with a previous report.25
Here, we studied 20 SCD patients, who received two
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different types of analgesic treatment during two sepa-
rate VOCs with time interval between VOCs of at least
6 months. The multimodal analgesic treatment was
started in both groups within 1 hour from the arrival in
the ED. In the first VOC episode, pain management was
performed by multimodal analgesia with administration
of a continuous intravenous infusion of ketorolac
(0.86 mg/kg/day), tramadol (7.2 mg/kg/day), and meto-
clopramide (0.57 mg/kg/day) for a maximum of 72
hours (TK treatment). In the second group of treatment
(n = 20), pain management was performed by multi-
modal analgesia with the administration of the same
pharmacological protocol with the addition of fentanyl
buccal tablet (FBT) 100 lg in single administration after
three hours from the beginning of multimodal analgesia
(TKF treatment). FBT was repeatable if requested by the
patient due to insufficient analgesia, from 30 minutes
after the first dose to a maximum cumulative dosage of
400 lg/24 hours. In respect to various fast-acting for-
mulations of oral fentanyl, FBT was chosen because it
seems to reach a higher plasma concentrations com-
pared to other fentanyl preparations such as oral
transmucosal fentanyl citrate (OTFC).20 During each
VOC episode, pain intensity was recorded using an 11-
point pain scale (visual analogue scale, VAS) at admis-
sion and at 3, 6, 12, 18, and 24 hours from the
beginning of each treatment. At the same time intervals,
we also evaluated (i) patients pain relief (PR) with a scale
from 0 (no PR) to 10 (complete PR); (ii) the level of
anxiety with a scale from 0 (no anxiety) to 10 (the worst
possible anxiety); (iii) patients mood level with a scale
from 0 (worst mood) to 10 (best mood); iv) patients
sedation level with a scale from 0 (deep sedation) to 10
(no sedation). The primary efficacy measure was the
time-weighted sum of pain intensity differences from 3
to 24 hours after the administration of the drugs (time-
weighted SPID24). The PID (pain intensity difference)
was calculated at each time interval by subtracting the
baseline from the actual pain intensity score. SPID24 was
derived as follows:
SPID24 ¼
X
½TðiÞ  Tði1Þ  PIDðiÞ
whereT(i) is the scheduled time, andPID(i) is the PID score
at time i. The secondary efficacy measure was time-
weighted total pain relief (TOTPAR), calculated consid-
ering painrRelief (PR) instead of PID. Changes in
patient’s anxiety during treatment was evaluated as
time-weighted SAID24 (sum of anxiety intensity differ-
ences from 3 to 24 hour) calculated in the same way as
SPID24. The type and the duration of analgesic therapy as
well as the number of additional doses of FBT were
recorded. The safety and tolerability profile of the
treatments were assessed based on possible adverse
effects (AEs) reported by the patients and recorded by
the investigators as previously reported.15 Despite the
availability of specific and reliable questionnaires aimed
to assess drug side effects in chronic pain,26 equivalent
tools to be used in acute pain in the context of emergency
departments are not present. Thus, we chose to rely on
patient report and usual clinical and instrumental mon-
itoring as deemed appropriate for this kind of therapy.
The incidence of nausea or vomiting, sedation, respira-
tory distress, and renal failure was actively searched by
the investigators. In particular, arterial peripheral oxy-
gen saturation (SpO2%) was measured by a pulse oxime-
ter (SATLITE-TRans, Datex, Helsinki, Finland) at the
admission and at the different time points. Patients were
asked to quantitate nausea and sedation on a 10-point
scale. At 72 hours, patients satisfaction about the treat-
ment was collected using a five-point scale (0 not
satisfied, 1 partially satisfied, 2 satisfied enough, 3
adequately satisfied, and 4 fully satisfied). Data were
collected by blinded physicians and nurses.
Statistical Analysis
The statistical analysis was performed comparing data
from the two treatments of patients with VOC. As no
data followed Gaussian distribution (as tested with
Kolmogorov Smirnov) nor standard deviations were
consistently equal (as tested with Bartlett), nonpara-
metric statistics were implemented. The evaluation of
treatment’s efficacy, tolerability, and safety (SPID24
and other cumulative calculated measures) was per-
formed using the two tailed Wilcoxon signed-rank test
comparing the two treatments. Friedman’s nonpara-
metric test for related samples followed by Dunn
correction for multiple comparisons was used to
compare the time course for each parameter at each
interval. A P value < 0.05 was considered statistically
significant. Descriptive statistics were reported in terms
of medians and interquartile range (IQR) for quanti-
tative variables and in terms of absolute frequencies
and percentages for qualitative variables. Statistical
analysis was performed using MedCalc for Windows,
version 11.3.0.0 (MedCalc Software, Ostend, Bel-
gium) and GraphPad Prism for Windows, version
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5.01 and 6.01 (GraphPad Software, San Diego, CA,
USA).
RESULTS
In this study, we evaluated the impact of FBT as
breakthrough pain medication in the early phase of pain
management during severe VOCs in adult patients with
SCD. We treated 20 SCD patients during 2 separate
severeVOCepisodes in the time interval of the study. The
demographic, hematological, and biochemical charac-
teristics of SCD patients on steady state and at the
admission to the hospital for acute severe VOCs are
reported in Table 1. A large portion of patients were
homozygous for HbS (SS). At baseline (steady state),
patients demonstrated chronic hemolytic anemia (Hb
median 11 g/dL; LDHmedian 484 U/L) in the absence of
inflammatory signs (Table 1). At admission to the ED for
acute severe VOCs, the pain localization referred by
patients was similar in both VOC episodes and in
agreement with previous report by McClish et al.27 A
significant reduction in Hb levels (Hb median 8 g/dL)
compared to steady state and increased LDH levels
(median 750 and 698 U/L) associated with inflammatory
response (C-reactive protein, CRPmedian 23 and 28mg/
dL) were observed in SCD patients (Table 1). In each
VOCs, we focused on the first 24 hours after patient
admission to ED to evaluate the efficacy of analgesiawith
and without FBT associated with multimodal analgesia.
In both TK and TKF treatments, the VAS pain was
significantly reduced at 6 hours, reaching a plateau
thereafter in TK treatment (Figure 1A). In TKF treat-
ment, the VAS pain –markedly reduced at 6 hours –was
significantly and continuously lower compared to TK at
6 and 12 hours of treatment (Figure 1A). All TFK
patients had a reduction in VAS greater than 30% both
at 6 and 12 hours, while only one patient (5%) had a
30% reduction at 6 hours and 4 (20%) at 12 hours in
TK group. A 50% reduction in pain intensity was
present in 12 (at 6 hours) and 18 (at 12 hours) in TFK
group. No patient had such reduction in VAS in TK
treatment. The differences in proportions were statisti-
cally significant (Fisher exact test P < 0.0001). VAS pain
relief was higher in TKF compared to TK treatment
following FBT administration, with P < 0.0001 at 6 and
P = 0.0213 at 24 hours, and only slightly higher (0.070)
at 18 hours (Figure 2A). The time-weighted TOTPAR
as secondary efficacy measurement of FBT clinical
impact was significantly lower in TK compared to
TKF treatment (TK vs TKF, P < 0.0001). The reduction
in pain intensity assessed by PID was significantly higher
in TKF compared to TK treatment at 6 and 12 hours, of
treatment (and P for increase at 18 hours was 0.07),
suggesting a clinical improvement of pain control in
TKF compared to TK one (Figures 1A, 2B). SPID24, as
primary efficacy measurement, was significantly higher
in SCD patients treated with TKF than with TK (TK vs
TKF, P < 0.0001). Due to insufficient analgesia, two of
20 SCD patients required a second administration of
FBT at 30 minutes after the first one; both patients were
homozygous for HbS.
During VOCs, we evaluated the impact of FBT on
patients’ anxiety. As shown in Figure 3(A), the reduction
of patients’ anxiety was higher in TKF compared to TK
treatment. The SAID24, as secondary efficacy measure-
ment, was significantly lower in TK treatment compared
Table 1. Patients Characteristics on Steady State and at the Hospital Admission for Severe VASO-Occlusive Crisis
(VOCs)
Parameters Patients (n = 20)
Age (years) 22 (17.0 to 28.0)
Gender (M/F) 9/11
SS/bS 16/4
On HU 12/20
Steady state (n = 20) Admission for VOCs (TK; n = 20) Admission for VOCs (TKF; n = 20)
Hb (g/dL) 11 (9.0 to 11.7) 8 (6.7 to 9)* 8 (6.5 to 8.9)*
Creatinine (mg/dL) 0.7 (0.3 to 1.5) 1.2 (0.9 to 1.8) 1.1 (0.9 to 1.4)
LDH (U/L) 484.0 (310.2 to 1104.2) 750 (512 to 982)* 698 (505 to 897)*
Albumine (g/L) 44.3 (35.6 to 49.7) 48 (46 to 51) 49 (46 to 53)
CRP (mg/L) 3.0 (1.0 to 15.8) 23 (17 to 28)* 28 (16 to 29)*
Pain site(s) during VOCs – 80% of the pts: low back 70% of the pts: low back
10% of pts: extremities 18% of pts: extremities
10% of the pts: thorax 12% of the pts: thorax
Duration of hospitalization (days) – 4.5  0.8 3.8  1.2
Data are expressed as median (range). M, male; F, female; Hb, hemoglobin; HbS, sickle hemoglobin; HbF, fetal hemoglobin; LDH, lactate dehydrogenase; CRP, C-reactive protein; TK,
tramadol plus ketorolac group; TKF, pts: patients; tramadol plus ketorolac plus fentanyl buccal tablet treatment; *P < 0.05 compared to steady state.
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toTKF, indicating the clinical efficacy of FBTonpatients’
anxiety (TK vs TKF, P < 0.0001). As the acute pain
during VOCs is inscribed in chronic pain experience,
which affects pain memories and global emotional
insights of SCD patients,7,8 we evaluated patients’ mood
during the analgesic treatments. We found that VAS
patients’ mood was significantly greater in TKF than in
TK treatment at 6, 12, and 18 hours of study (Figure 3B)
and nearly significantly greater at 24 hours (P = 0.06).
During analgesic treatment, we evaluated patients’
sedation as a possible opioid-related side effect. In TKF-
treated SCD patients, sedation was greater than in TK
treatment at 6 hours and 12 hours, while no significant
differenceswereobservedat18and24 hours (Figure 3C).
A
B
C
Figure 1. Time course of (A) VAS pain, (B) median SpO2 (%), and
(C) patients’ satisfaction of pain treatment for SCD patients
treated with either TK: tramadol (7.2 mg/kg/day) and ketorolac
(0.86 mg/kg/day) or TKF: tramadol (7.2 mg/kg/day), ketorolac
(0.86 mg/kg/day) and fentanyl buccal tablet (FBT, 100 lg). Data
are expressed as median and interquartile range (n = 20 each
treatment; °P < 0.05 compared to time 0 in TK treatment;
^P < 0.05 compared to time 0 in TKF treatment; *P < 0.05 TK vs
TKF treatment at the different time points). The arrow indicates
when FBT was administrated in TKF treatment. Patients’ satisfac-
tion was recorded at 72 hours with a five-point scale (0 not
satisfied, 1 partially satisfied, 2 satisfied enough; 3 adequately
satisfied, and 4 fully satisfied) for the two investigational
treatments: The horizontal line for each group represents the
median value, and the vertical bars represent the interquartile
range (n = 20 each group; *P < 0.05 compared to TK treatment).
A
B
Figure 2. VAS Pain Relief and PID. (n = 20 each treatment;
°P < 0.05 compared to time 0 in TK treatment; ^P < 0.05
compared to time 0 in TKF treatment; *P < 0.05 TK vs TKF
treatment at the different time points).
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We then evaluated the peripheral oxygen saturation
(SpO2%) in TK and TKF treatment as reduced periph-
eral oxygen saturation (SpO2) and alveolar ventilation
have been described in SCD patients during severe
VOCs28(Needleman et al., 2002). As shown in Fig-
ure 1(B), SpO2 levels were significantly higher in TKF
than in TK treatment at 6, 12, 18, and 24 hours of
study. No major side effects were recorded either in TK-
or TKF-treated SCD patients. In particular, no nausea,
vomit, or respiratory depression episodes were recorded.
We also collected data on patients’ satisfaction during
TK and TKF treatment. As shown in Figure 1(C), we
found that patients’ satisfaction was greater in TKF than
in TK treatment. We did not find significant differences
in time of hospitalization between TKF and TK treat-
ment as shown in Table 1.
DISCUSSION
The control of acute pain in the early phase of severe
VOCs is still unsatisfactory and negatively impacts SCD
patients’ quality of life.7, 8, 29 The acute pain of VOCs is
generally managed with increasing or rescue dose of
around-the-clock medication such as oral morphine.6
However, studies in both human subjects and mouse
models for SCD have shown that treatment with
morphine is associated with increase rate of acute chest
syndrome, renal toxicity, and peripheral system dysfunc-
tion.6 In addition, the accelerated clearance of morphine
observed in SCD patients requires the development of
alternative or additional therapeutic strategies in con-
trolling acute pain of VOCs.30–32 In SCD, VOCs are
characterized by severe continuous pain with exacerba-
tion of acute pain most likely due to sudden temporary
local enhanced vasoconstriction phenomena that are
favored by abnormal parasympathetic vascular response,
promoting acute ischemic pain.33,34 The temporal char-
acteristics, the intensity, and the mechanism of this type
of pain might be considered as a breakthrough pain as
defined by the literature35 (Davies et al., 2009) (Fig-
ure 2). Here, we show that FBT used as breakthrough
painmedication significantly improved pain relief during
early phase of severe VOCs in adult patients with SCD.
This finding is important as the adequate and early
control of acute pain in VOCs might reduce more severe
sickle cell-related complications.6 The increase in
SPID24, as primary efficacy measure, and in TOTPAR
(total pain relief), as secondary efficacy measure, vali-
dates the clinical improvement of pain management with
FBT associated with the infusion of ketorolac and
tramadol (TK) in the early phase of VOCs. Indeed, the
reduction in VAS pain was maintained from 6 to
24 hours after FBT administration, without hyperalge-
sia, acute tolerance, or blunted response.6, 22
These findings might be related to the pharmacologic
characteristics of oral fentanyl, which becomes rapidly
bioavailable at high plasma concentration, bypassing
A
B
C
Figure 3. VAS. Anxiety – Mood – Sedation (n = 20 each treat-
ment; °P < 0.05 compared to time 0 in TK treatment; ^P < 0.05
compared to time 0 in TKF treatment; *P < 0.05 TK vs TKF
treatment at the different time points).
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the cytochrome P450 metabolism.20, 21 In addition, oral
mucosa as route of drug delivery offers clear advantages
compared to other fentanyl formulations in the context
of patients management in EDs.22,36 Although one
limitation of the present study is that it is not
randomized, the sample size is appropriated to evaluate
the clinical impact of FBT on acute pain control in
SCD, based on the recently reported power analysis on
the use of intranasal fentanyl for acute pain control in
children with SCD.25 The additional observation that
SAID24 (sum of anxiety Intensity differences), as
secondary efficacy measure, was increased in TKF
treatment and was paralleled with an amelioration of
patients mood supports the clinical importance of FBT
associated with multimodal analgesia in treatment of
acute pain related to VOCs. The SCD patients’ satis-
faction was higher in TKF than in TK treatment, in
agreement with other reports in cancer and noncancer
pain origin.20, 37 It is of interest to note that the
improved pain control obtained with FBT in the TKF
treatment, resulted in significant amelioration of the
peripheral oxygen, suggesting an improvement of gas
exchange in the presence of an optimized pain con-
trol.28
Based on these data, we postulated that pain crisis in
SCD are characterized by continuous pain with exac-
erbated acute pain related to the dynamic vaso-occlu-
sive phenomena that are negatively affected by
enhanced vasoconstriction, requiring a breakthrough
pain medication strategy (Figure 2). Our results are also
supported by a recent communication on the use of
intranasal fentanyl in management of acute pain in
pediatric sickle cell patients (B.T. Akinsola, R. Hag-
bom, A. Zmitrovich, P. Kavanagh, A. Ashkouti, A.
Fletcher, N. Vinson, H. Simon, H. Fleming, S. Jain, O.
Adisa, C. Dampier, C.R. Morris, 2014, abstract
presented at the 56th ASH Annual Meeting in San
Francisco). There are some limitations of the present
study mainly related to the absence of a placebo control
group. However, our data together with the recent
report by Akinsola generate the preliminary evidence
for the use of FBT in management of acute VOCs in
SCD, which will be further investigated in larger
multicenter study.
Thus, we suggest FBT as BTP drug might be a
powerful and feasible tool in early management of acute
pain in ED as reported in other acute noncancer pain.22
Future studies should be carried out to further evaluate
the impact of FBT on acute pain management in EDs in a
large cohort of SCD patients.
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